13 terminated, 3 withdrawn, 1 completed. 17 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 13, Withdrawn 3, Completed 1 |
| Phase 1 | 6 | Terminated 4, Completed 1, Withdrawn 1 |
Follow magrolimab: new trials by email Literature Review of magrolimab trials Research Report on magrolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants Sabatolimab, Magrolimab, Azacitidine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2024-12-20 | 2024-04-11 | |
| Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS Magrolimab, 7+3, CPX-351 - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Withdrawn | Uwe Platzbecker | 2024-03-31 | 2024-02-12 | |
| Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma Pembrolizumab, Magrolimab, cetuximab - Head Neck, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2023-11-28 | 2025-10-22 |
| An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Magrolimab, Rituximab, CAR T leukapheresis - Large B-cell Lymphoma, B-cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-09-30 | 2023-11-13 | |
| A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) Decitabine/Cedazuridine, Magrolimab - Myelodysplastic Syndromes | Phase 2 | Terminated | Astex Pharmaceuticals, Inc. | 2 | 2023-06-27 | 2024-10-02 |
| Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) Magrolimab, Bevacizumab, Irinotecan - Metastatic Colorectal Cancer | Phase 2 | Terminated | Gilead Sciences | 77 | 2022-07-08 | 2025-07-01 |
| Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma Magrolimab, Pembrolizumab, PET/CT - Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Terminated | Ranjana Advani | 8 | 2022-06-21 | 2026-06-30 |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer Magrolimab, Nab-Paclitaxel, Paclitaxel - Triple-Negative Breast Cancer | Phase 2 | Terminated | Gilead Sciences | 92 | 2021-12-14 | 2025-11-04 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Magrolimab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 2 | Terminated | Gilead Sciences | 36 | 2021-11-09 | 2025-05-02 |
| Study of Magrolimab in Patients With Solid Tumors Magrolimab, Docetaxel - Solid Tumor | Phase 2 | Terminated | Gilead Sciences | 106 | 2021-10-01 | 2025-05-08 |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma Magrolimab, Pembrolizumab, Docetaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Gilead Sciences | 193 | 2021-09-07 | 2025-11-19 |
| Study of Magrolimab Combinations in Participants With Myeloid Malignancies Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies | Phase 2 | Terminated | Gilead Sciences | 54 | 2021-06-28 | 2025-03-20 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 110 | 2020-07-28 | 2026-04-23 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 272 | 2019-06-01 | 2026-08-03 |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Magrolimab, Rituximab, Gemcitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 178 | 2016-11-21 | 2025-05-29 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer Magrolimab, Cetuximab - Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Gilead Sciences | 78 | 2016-11-02 | 2021-03-01 |
Leukemia, Myeloid, Acute (3) · Colorectal Neoplasms (2) · Myelodysplastic Syndromes (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Transitional Cell (1) · Hodgkin Disease (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Mycosis Fungoides (1) · Recurrence (1) · Sezary Syndrome (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Gilead Sciences (8) · M.D. Anderson Cancer Center (3) · Astex Pharmaceuticals, Inc. (1) · Hoffmann-La Roche (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · Ranjana Advani (1) · Uwe Platzbecker (1)
United States (14) · United Kingdom (6) · Australia (5) · France (4) · Spain (4) · Hong Kong (3) · Belgium (2) · Canada (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Taiwan (2) · Czechia (1) · Greece (1)
Michael S Khodadoust (1) · Naval G Daver (1) · Paolo Strati, MD (1) · Ranjana H Advani, MD (1) · Renata Ferrarotto, M D (1) · Uwe Platzbecker, Prof. Dr. (1)
PMID 37651261, PMID 39213421, PMID 39293083, PMID 40364806, PMID 40485906
2016 (1), UM1CA186717 (1)